Skip to main content

Emergent BioSolutions

Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax

Developing Products that Address Emerging Infectious Diseases

Emergent BioSolutions Initiates Phase 1 Clinical Study of Zika Virus Immune Globulin Therapeutic

Expanding our Manufacturing Capabilities

Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility

Preventing the Spread of a Global Epidemic

CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine

Expanding Licensure of BioThrax Globally

Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European Countries

Explore more stories Scroll down